PatchG
2021-08-02
Too early but Pharma always ready for legal
Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report<blockquote>辉瑞、Moderna 提高向欧盟供应的疫苗价格:报告</blockquote>
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":805809834,"tweetId":"805809834","gmtCreate":1627867966728,"gmtModify":1633755801660,"author":{"id":4088070664933270,"idStr":"4088070664933270","authorId":4088070664933270,"authorIdStr":"4088070664933270","name":"PatchG","avatar":"https://static.tigerbbs.com/bf19f71e0afadca38d3167c641e1c912","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Too early but Pharma always ready for legal </p></body></html>","htmlText":"<html><head></head><body><p>Too early but Pharma always ready for legal </p></body></html>","text":"Too early but Pharma always ready for legal","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/805809834","repostId":1162208746,"repostType":4,"repost":{"id":"1162208746","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627865676,"share":"https://www.laohu8.com/m/news/1162208746?lang=zh_CN&edition=full","pubTime":"2021-08-02 08:54","market":"us","language":"en","title":"Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report<blockquote>辉瑞、Moderna 提高向欧盟供应的疫苗价格:报告</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1162208746","media":"Benzinga Earnings","summary":"Pfizer, Inc. and Moderna, Inc., which have already minted billions of dollars from their respective ","content":"<p><b>Pfizer, Inc.</b> and <b>Moderna, Inc.</b>, which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.</p><p><blockquote><b>辉瑞公司。</b>和<b>现代公司。</b>这些公司已经从各自的 COVID-19 疫苗中赚取了数十亿美元,并且仍然准备赚取更多收入。</blockquote></p><p> <b>What Happened:</b>Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.</p><p><blockquote><b>发生了什么:</b>据英国《金融时报》周日报道,辉瑞和Moderna都与欧盟重新谈判了疫苗供应合同。</blockquote></p><p> The contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with <b>BioNTech SE</b> showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.</p><p><blockquote>报告称,在第三阶段数据发布后,供应多达21亿剂疫苗的合同条款进行了修改。辉瑞正在与辉瑞合作开发的mRNA疫苗的后期研究<b>生物科技公司</b>显示出95%的疫苗效力,而Moderna开发的类似类别的疫苗拥有94.1%的疫苗效力。</blockquote></p><p> In comparison,<b>Johnson & Johnson's</b> single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.</p><p><blockquote>相比之下,<b>强生公司</b>在美国授权使用的单剂量注射显示出72%的总疗效。</blockquote></p><p> <b>AstraZeneca plc's</b> COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.</p><p><blockquote><b>阿斯利康公司</b>由灭活腺病毒制成的新冠肺炎疫苗在接受两剂后15天或更长时间,被发现在降低症状性疾病风险方面有76%的有效性。</blockquote></p><p> Additionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.</p><p><blockquote>此外,强生和阿斯利康的授权疫苗与严重血栓的零星发生率有关。</blockquote></p><p> Pfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.</p><p><blockquote>辉瑞和Moderna已经设法扩大了疫苗的年龄范围,将青少年包括在内,他们还在儿科人群中进行试验。这些公司正在研究可能被证明对变异有效的加强剂量,以及变异特异性疫苗。</blockquote></p><p> The FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.</p><p><blockquote>英国《金融时报》报道称,辉瑞已将其疫苗价格从最初签订的每剂15.50欧元(18.39美元)提高到19.50欧元。Moderna shot的价格已经从22.60美元提高到25.50美元。</blockquote></p><p> <b>Why It's Important:</b>Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.</p><p><blockquote><b>为什么重要:</b>辉瑞和Moderna能够决定条款,因为世界仍在努力应对新型冠状病毒,特别是随着变种的出现。</blockquote></p><p> The EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.</p><p><blockquote>据英国《金融时报》报道,欧盟也面临着采购更多供应的压力,因为欧盟国家谴责成员国之间疫苗分配不公。</blockquote></p><p> Pfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.</p><p><blockquote>辉瑞上周发布的第二季度业绩显示,这家制药巨头第二季度的 COVID-19 疫苗收入约为 80 亿美元。该公司还将 2021 年疫苗收入预测从 260 亿美元上调至 335 亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report<blockquote>辉瑞、Moderna 提高向欧盟供应的疫苗价格:报告</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report<blockquote>辉瑞、Moderna 提高向欧盟供应的疫苗价格:报告</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-08-02 08:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b> and <b>Moderna, Inc.</b>, which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.</p><p><blockquote><b>辉瑞公司。</b>和<b>现代公司。</b>这些公司已经从各自的 COVID-19 疫苗中赚取了数十亿美元,并且仍然准备赚取更多收入。</blockquote></p><p> <b>What Happened:</b>Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.</p><p><blockquote><b>发生了什么:</b>据英国《金融时报》周日报道,辉瑞和Moderna都与欧盟重新谈判了疫苗供应合同。</blockquote></p><p> The contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with <b>BioNTech SE</b> showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.</p><p><blockquote>报告称,在第三阶段数据发布后,供应多达21亿剂疫苗的合同条款进行了修改。辉瑞正在与辉瑞合作开发的mRNA疫苗的后期研究<b>生物科技公司</b>显示出95%的疫苗效力,而Moderna开发的类似类别的疫苗拥有94.1%的疫苗效力。</blockquote></p><p> In comparison,<b>Johnson & Johnson's</b> single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.</p><p><blockquote>相比之下,<b>强生公司</b>在美国授权使用的单剂量注射显示出72%的总疗效。</blockquote></p><p> <b>AstraZeneca plc's</b> COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.</p><p><blockquote><b>阿斯利康公司</b>由灭活腺病毒制成的新冠肺炎疫苗在接受两剂后15天或更长时间,被发现在降低症状性疾病风险方面有76%的有效性。</blockquote></p><p> Additionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.</p><p><blockquote>此外,强生和阿斯利康的授权疫苗与严重血栓的零星发生率有关。</blockquote></p><p> Pfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.</p><p><blockquote>辉瑞和Moderna已经设法扩大了疫苗的年龄范围,将青少年包括在内,他们还在儿科人群中进行试验。这些公司正在研究可能被证明对变异有效的加强剂量,以及变异特异性疫苗。</blockquote></p><p> The FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.</p><p><blockquote>英国《金融时报》报道称,辉瑞已将其疫苗价格从最初签订的每剂15.50欧元(18.39美元)提高到19.50欧元。Moderna shot的价格已经从22.60美元提高到25.50美元。</blockquote></p><p> <b>Why It's Important:</b>Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.</p><p><blockquote><b>为什么重要:</b>辉瑞和Moderna能够决定条款,因为世界仍在努力应对新型冠状病毒,特别是随着变种的出现。</blockquote></p><p> The EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.</p><p><blockquote>据英国《金融时报》报道,欧盟也面临着采购更多供应的压力,因为欧盟国家谴责成员国之间疫苗分配不公。</blockquote></p><p> Pfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.</p><p><blockquote>辉瑞上周发布的第二季度业绩显示,这家制药巨头第二季度的 COVID-19 疫苗收入约为 80 亿美元。该公司还将 2021 年疫苗收入预测从 260 亿美元上调至 335 亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162208746","content_text":"Pfizer, Inc. and Moderna, Inc., which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.\nWhat Happened:Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.\nThe contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with BioNTech SE showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.\nIn comparison,Johnson & Johnson's single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.\nAstraZeneca plc's COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.\nAdditionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.\nPfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.\nThe FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.\nWhy It's Important:Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.\nThe EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.\nPfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":867,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/805809834"}
精彩评论